Our data provide compelling evidence that imiquimod stimulates NF-κB, IL-8 and TNF-α expression in keratinocytes via TLR7, and it is tempting to propose that modulation of these pathways could be an interesting candidate for the treatment of inflammatory skin diseases. The gene discussed is NFKB1; the disease is inflammatory skin disease.